Several phase III clinical trials targeting IGF-1R with small molecule inhibitors have so far failed due to side effects such as hyperglycemia and metabolic syndrome caused by the homology of IGF-1R and insulin receptor (IR) and IGF elevation in response to disruption of glucose homeostasis. The gene discussed is INSR; the disease is metabolic syndrome.